To examine the cross-sectional association between functional performance and Alzheimer's disease (AD) neuroimaging biomarkers in individuals without dementia (cognitively unimpaired (CU), and those with mild cognitive impairment (MCI)). DESIGN: Cross-sectional. SETTING: Olmsted County, Minnesota. PARTICIPANTS: Population-based Mayo Clinic Study of Aging (MCSA) participants (aged ≥ 50, mean age 71.3 ± 10.2; 53.4% male; 28.3% apolipoprotein (APO)E ε4 allele carriers, 1,578 CU, 204 MCI) who underwent 11 C-Pittsburgh compound B ( 11 C-PiB) positron emission tomography (PET) (N=1,782).
R esearch in the field of cognitive aging is being focused on strategies for early detection of individuals with underlying Alzheimer's disease (AD) pathology before clinical symptomatology is evident. Persons with preclinical disease could be candidates for early (secondary) preventive interventions to prevent or delay clinical symptoms. Although functional impairment is required for the definition of dementia, subtle changes are likely in the preclinical phase but have not been adequately assessed. 1 It is important to determine which changes in activities of daily living (ADL), particularly instrumental activities of daily living (IADL; requiring more complex skills) can be detected at an early stage and may be early markers of cognitive decline and herald changes in AD pathology. The Clinical Dementia Rating Scale (CDR) is a global scale used to assess severity of dementia and simultaneously captures functional and cognitive performance. CDR and CDR Sum of Boxes (CDR-SOB) scores have been shown to be significantly associated with brain amyloid burden in individuals with AD. 2, 3 IADL impairment has been associated with greater amyloid burden in individuals with mild cognitive impairment (MCI), 4 and deteriorating ADL ability in individuals with AD have been associated with greater pathological burden (neuritic plaque and neurofibrillary tangle counts). 5 Decline in some IADL might start earlier in the disease course, even at the stage of MCI. 1, 6 Greater IADL impairment (as assessed using the informant-based Functional Activities Questionnaire (FAQ)) 7 has been associated with greater global Pittsburgh compound B (PiB) retention in individuals with MCI but not those with cognitive impairment. 4 An association between greater IADL disability and greater burden of brain amyloid has also been demonstrated in community-dwelling older adults with good functional status who reported memory complaints to their general practitioner. 1 Studies also support an association between IADL impairment and AD neurodegenerative patterns in magnetic resonance imaging (MRI) studies 8 and brain hypometabolism. 9 The objective of the current study was to examine the association between daily functioning (assessed using the CDR and FAQ) and AD biomarkers in individuals without dementia (CU and MCI).
METHODS

Study population
The study design and protocol of the Mayo Clinic Study of Aging (MCSA) has been reported in detail previously. 10, 11 In brief, Rochester Epidemiology Project (REP) 12 resources were used to number Olmsted County, Minnesota residents aged 70 to 89 on October 1, 2004, and an age-and sexstratified random sample was invited to participate in the MCSA. 10 Ongoing recruitment has maintained the size of the study sample. Recruitment of participants aged 50 to 69 years old was initiated in 2012. MRI was initiated in 2005 and 11 C-PiB positron emission tomography (PET) scans in 2008. As of March 2017, 11 C-PiB PET data were available for 1,782 MCSA participants, 1,763 of whom had CDR data available, and 1,743 had FAQ data.
Standard Protocol Approvals, Registrations, and Participant Consent
The institutional review boards of the Mayo Clinic and Olmsted Medical Center approved the study. All participants provided written informed consent before study participation.
Clinical evaluation and diagnostic assessment
A nurse or a study coordinator and a physician evaluated each participant, and a psychometrist administered neuropsychological tests. The nurse or study coordinator collected demographic information, asked questions about memory; and administered the CDR 13 20, 21 and visuospatial skills (Block Design and Picture Completion, from the Wechsler Adult Intelligence Scale-Revised). 19 The raw scores from each test were transformed into age-adjusted scores using independent normative data. 22 Domain scores were obtained by averaging the adjusted scaled scores within each domain and then scaled to allow for comparisons across domains. For each domain, a score greater than 1 standard deviation (SD) below the age-specific mean was considered to be possible cognitive impairment. At a weekly conference, the nurse or study coordinator, the physician and a neuropsychologist discussed all the information for each subject and the final diagnosis (CU, MCI, dementia) was made according to consensus decision. 10, 11 Individuals who performed in the normative range and did not meet criteria for MCI 23 or dementia 24 were classified as CU.
Covariates
For analytical assessment of performance on the various tests, the raw scores for tests in each domain were z-scored, averaged, and scaled to create domain-specific cognitive z-scores. A global z-score for overall performance was also created by averaging and scaling the 4 domain z scores. APOE ε4 genotype was determined from blood drawn at the baseline assessment. Medical comorbidities were abstracted from participant medical records using the REP medical records-linkage system. The chronic disease burden was assessed using a weighted Charlson Comorbidity Index 25 score based on electronic diagnosis codes (Hospital International Classification of Diseases Adapted, International Classification of Diseases, Ninth and Tenth Revisions) using the REP resources.
C-PiB PET acquisition
Details are presented in previous reports. [26] [27] [28] A global PIB standardized uptake value ratio was calculated from weighted median pixel values in regions of interest (ROIs) from both hemispheres for the parietal, temporal, prefrontal, orbito frontal, precuneus, anterior cingulate, and posterior cingulate regions and referenced to the cerebellar grey matter crus. An abnormal (high; A+) 11 C-PiB-PET retention ratio was defined as standardized uptake value ratio greater than 1.42. 29 The first 11 C-PiB-PET scan was used in the current analysis.
MRI measure acquisition
All MRI images were acquired on 3T GE MRI (GE Medical Systems, Milwaukee, WI) and the cortical surface was parcellated using Freesurfer version 5.3. A composite thickness measure representing an AD signature cortical thickness was computed to assess AD-related neurodegeneration based on individual cortical thickness for ROIs from the entorhinal, inferior temporal, middle temporal, and fusiform cortex from both hemispheres. 30 Abnormal (reduced) AD signature cortical thickness (N+) was defined as less than 2.67 mm. 29 Cortical thickness data (N+/N-) were available for 1749 participants.
Assessment of functional performance
Functional performance was assessed according to the CDR 13 and FAQ. 14 The CDR measures impairment caused by cognitive loss and obtains information on an individual's performance in 6 cognitive and functional domains (memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care). 2, 13 The global CDR score (0=no dementia, 0.5=questionable dementia, 1=mild dementia, 2=moderate dementia, 3=severe dementia) is derived from the ratings in each domain, which range from 0 (no impairment) to 3 (severe impairment). The CDR-SOB is computed by summing the scores for each of the domain boxes (score ranges from 0 to 18). 2 We also computed the CDR-SOB for only the 3 functional domains, 31 which we call in the present study "CDR-SOB (functional)."
The FAQ is a 10-item questionnaire that assesses IADL (e.g., writing checks, assembling tax records, shopping alone for groceries, working on a hobby, turning off stove after use, traveling out of neighborhood, preparing a balanced diet). The informant rates the participant's abilities (0=normal; 1=has difficulty, but does by self; 2=requires assistance; 3=dependent; 8=not applicable (e.g., never did) was not scored), resulting in a score range from 0 to 30; higher scores indicate greater impairment. The FAQ was considered complete if 70% of the questions were answered; 1,508 participants completed all questions, 164 had 1 missing question, 59 had 2 missing, and 12 had 3 missing. Thirty-nine participants had less than 70% completion and were excluded from analyses. In current analyses, functional performance was assessed using the CDR-SOB (functional) and FAQ, over the previous year.
Statistical analysis
The CDR-SOB (functional) was square root-transformed, and the FAQ total score was log-transformed (ln (x+1) of FAQ total score), because they were substantially skewed. We examined cross-sectional associations between functional performance measures and A + and N + in individuals without dementia. The National Institute on Aging and Alzheimer's Association (NIA-AA) preclinical AD stages were defined according to amyloid and neurodegeneration status: A-N-, stage 0; A+N-, stage 1; A+N+, stages 2 and 3.
32-34 Suspected nonamyloid pathophysiology (SNAP) was defined as A-N +. 34 For these cross-sectional analyses, we used binary (for binary outcomes; A-/A + or N-/N+) or multinomial (for categorical outcomes; A/N biomarker combinations) logistic regression models. For evaluation of possible confounding or effect modification, analyses were also performed stratifying according to cognitive status (CU, MCI) and in the 2 cognitive status groups. We adjusted the binary logistic and multinomial models for age at PiB PET scan, sex, education, APOE ε4 allele status, and global cognitive z-score. We ran models including only participants with 100% complete FAQ questionnaires, and estimates were very similar, so we report analyses including all FAQ questionnaires with 70% of questions answered. Further adjustment for Charlson Comorbidity Index (which considers disease severity and was developed to assess effect of disease burden on health outcomes) 25, 35 did not change the estimates appreciably, and it is not included in the presented models. In stratified logistic regression models, we adjusted for age at PiB PET scan, sex, education, and APOE ε4 allele status, using cognitive status (CU, MCI) as strata. Potential effect modification by age was examined using interaction terms in the models, but interaction terms were not statistically significant. Associations were considered significant at a 2-tailed p-value<.05. Analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC) and Stata/SE version 15.1 (StataCorp LP, College Station, TX). Table 1 presents characteristics of MCSA participants without dementia according to amyloid (N=1,782) and neurodegeneration (N=1,749) status. Overall, mean age was 71.3 ± 10.2, 53.4% were male, and 28.3% were APOE ε4 allele carriers. Individuals with A + or N + were significantly older, had lower mean global cognitive z-score and Short Test of Mental Status score, and were more likely to have CDR-SOB (functional) and FAQ total scores greater than 0 than those with A-or N-, respectively. There were 800 (45.7%) individuals with A-N-, 223 (12.8%) with A+N-, 379 (21.7%) with A-N+, and 347 (19.8%) with A+N + biomarkers. There was a higher percentage of participants with CDR-SOB (functional) >0 or FAQ total score>0 in the A-N+ and A+N+ biomarker groups in both CU (p<.001) and participants with MCI (p<.001) (Figure 1 ).
RESULTS
Participant Characteristics
MCSA Participants with PET studies (vs MCSA participants without PET studies) were more likely to be male (p=.001), be younger (p<.001), have more education (p<.001), and have a higher global cognitive z-score (<.001) and less likely to have hypertension (p<.001), stroke (p=.001), congestive heart failure (p<.001), coronary heart disease (p<.001), and lower CDR-SOB (p=.040) and FAQ (p<.001) scores; there was no difference in frequency of APOE ε4 allele status carrier (p=.23) (results not shown).
Association between functional performance, amyloid, and neurodegeneration status
In the total sample, having a CDR-SOB (functional) score greater than 0 was associated with twice the odds of having A + (odds ratio (OR)=1.95, 95% confidence interval (CI) =1.04-3.67, p=.04), but significance was lost in the stratified model analysis that takes into account cognitive status (CU, MCI) ( Table 2) . Having a CDR-SOB (functional) score greater than 0 was also associated with almost 4 times the odds of having N+ (Table 2) . Individuals with a FAQ total score greater than 0 had greater odds of A + and N+. The associations between FAQ measures and A + and N + kept their significance in stratified models.
Impairment (>0) in the "community" and "home and hobbies" components were significantly associated with N+ (Supplementary Table S1 ). Participants with a FAQ total score 4 of greater had significantly higher odds of N + than those with a score less than 4 (Supplementary Table S2 ).
Association between functional performance, preclinical AD, and SNAP Individuals with a FAQ score greater than 0 were more than 3 times as likely to be A+N + as to be A-N-(OR=3.31, 95% CI=1.81-6.04) and were 2.6 times as likely to have SNAP as to be A-N-(OR=2.55, 95% CI=1. 45-4.46) (Table 3 ). There was 1 participant with a CDR-SOB (functional) score greater than 0 in the A-Ngroup, 1 in the A+N-group, 9 in the A-N + group, and 10 in the A+N + group, thus estimations were very imprecise and not included in the table.
DISCUSSION
We found that that higher FAQ scores were crosssectionally associated with A + and N + in MCSA participants without dementia and with A+N + (NIA-AA preclinical stages 2 and 3) and A-N + (SNAP) in CU participants.
CDR-SOB (functional), impairment in the "community" and "home and hobbies" CDR components were significantly associated with N+ in the total sample. The findings in this study supplement limited available information that supports an association between functional performance and AD neuroimaging biomarkers earlier in the dementia pathophysiology, when clinical symptomatology might not be evident. Current study findings are in line with previous studies suggesting that lower ADL and IADL abilities are associated with higher amyloid [1] [2] [3] [4] and studies showing an association between IADL impairment, brain hypometabolism, 9, 36, 37 and MRI biomarkers of neurodegeneration. 8, 38, 39 Cognitive impairment is a determinant of functional decline. 1 Because of the method of CDR assessment (involving informant information for functional status changes compared to previous performance), investigators have suggested that factors that usually affect cognitive tests, such as age, education, depression, or practice effects influence its 4 1 missing. 5 Assessed according to weighted Charlson Comorbidity Index score; 24 missing in abnormal (high) amyloid (A+; defined as 11 C-Pittsburgh compound B standardized uptake value ratio > 1.42) comparisons; 16 missing in abnormal (reduced) Alzheimer's disease signature cortical thickness (neurodegeneration (N +)) (defined as < 2.67 mm) comparisons. 6 Computed after scaling raw cognitive test scores (mean 0 ± 1) using data for cognitively normal subjects at baseline. Domain-specific z-scores are summed and scaled to obtain global z-scores; 87 missing in A + comparisons; 86 missing in N + comparisons. 7 19 missing. 8 39 missing. 9 33 missing. SD=standard deviation; CDR-SOB=Clinical Dementia Rating Scale Sum of Boxes; CDR (functional)=CDR-SOB for only the 3 functional domains (community affairs, home and hobbies, personal care); FAQ=Functional Activities Questionnaire (completed if 70% of questions answered).
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DECEMBER 2018-VOL. 66, NO. 12 FUNCTIONAL PERFORMANCE AND PRECLINICAL ADscore less, 40 although other researchers 4 prefer to adjust analyses for global cognitive impairment. In MCSA, the nurse or study coordinator uses the CDR during cognitive assessment of participants, as one of several assessments available; we chose to pursue analyses that also adjusted for global cognitive performance or considered (in stratified models) the consensus diagnosis of CU or MCI. Findings from both analyses were consistent that FAQ measures were associated with AD neuroimaging biomarkers, especially neurodegeneration, in the total sample. CDR-SOB (functional) was not significantly associated with A + when stratified analysis was used; CDR-SOB (functional) also included ADL related to personal care, which we expect to be impaired later in the AD trajectory.
Only a small minority of participants without dementia in the present study had less than perfect functional performance (4.2% had CDR-SOB (functional)>0; 13.2% had FAQ>0). In general, we would expect that impairment in function follows impairment in cognition, [41] [42] [43] with functional deficits not apparent until later in the AD process, but AD falls on a continuum, with variable clinical course and subtle impairment at the earliest stages. Subtle functional difficulties could be associated with AD biomarkers before detectable cognitive impairment 1 and baseline MRI imaging biomarkers could predict worsening of IADL over time across the AD spectrum 8 (CU, MCI, mild AD).
In the current study, the statistically significant association between FAQ measures and neurodegeneration was consistent in all analyses; this was not consistently the case for analyses related to A+, which might be important considering that biomarkers of neurodegeneration rather than of amyloid accumulation are directly related to cognitive symptoms. 43 We found that higher FAQ total score and FAQ total score greater than 0 were associated with the A+N + and A-N + biomarker groups in CU participants. These findings are important because persons with A-N + could have a greater rate of cognitive decline than those with A-N-, and individuals with A + and N + could have faster cognitive decline than those who are A-N-. 33 The current study is in agreement with a previous report 1 in community-dwelling older adults with good functional status who reported spontaneous memory complaints; although not all previous research 4 is in agreement. We need to explore further whether subtle functional limitations in individuals without dementia could be part of the earliest manifestations of AD neuroimaging biomarkers abnormality. CU individuals with poorer functional performance who are A+N + may be good candidates for surveillance and for preventive interventions when these become available.
In the present study, "community" and "home and hobbies" subscale impairments were significantly associated with neurodegeneration in individuals without dementia. Investigators have reported that individuals with amnestic MCI that progresses to AD had a higher baseline CDR orientation component score, 40 and individuals with MCI with IADL impairments on the CDR had more-widespread gray matter thinning in the frontal and parietal lobe areas, poorer cognitive performance, and a higher 2-year disease progression rate than individuals with MCI with similar CDR global scores but no IADL impairment. 44 There is a paucity of studies on the association between CDR domains and A + and N+, and additional research is needed to supplement our findings.
Previous studies suggest that FAQ total score can effectively discriminate between CU individuals and those with dementia, with a cut-off ranging from 5 to 8, and can discriminate between MCI and dementia, with an optimal cutoff between 5 and 6. 45 Although current findings might be of uncertain clinical significance, they underscore the need to develop measures of very early functional changes (as the NIA-AA workgroup suggested) 32 in persons at the earliest, or presymptomatic, stages of AD. 46 The study has limitations. The study was cross-sectional and we cannot assess causality. In addition, we lack information on tau PET imaging, and we cannot exclude that other unmeasured factors confounded estimations. Findings help generate research hypotheses for future studies. During the MCSA evaluation, the nurse or a study coordinator (one of the three independent evaluators) considered CDR during the participant's cognitive assessment. We tried to remedy this limitation by including the global cognitive score in the analysis models or using stratified models, but residual bias might have remained.
The study has also important strengths. Informants were not aware of participants' objective cognitive performance scores or amyloid or neurodegeneration status, thus avoiding recall bias. An informant assessed functional performance, avoiding limitations due to participants' cognitive status or factors that affect cognitive tests (e.g., education, depression).
Our observations add valuable information to limited available data that support an association between 4 Adjusted for age, sex, education, global cognitive z-score, and apolipoprotein (APO)E ε4 allele carrier status. For analysis related to A+, data were available for 532 participants with A + and 1,105 without overall for analyses related to CDR (functional) and 562 with A + and 1,141 without for analyses related to FAQ measures. For analysis related to N+, data were available for 674 participants with N + and 939 without overall for analyses related to CDR (functional) and 667 with N + and 927 without for analyses related to FAQ measures. 5 Comparison of > 0 vs 0 (reference) of CDR-SOB (functional) or FAQ measurement. 6 Adjusted for age, sex, education, and APOE ε4 allele status, stratifying according to cognitive status (unimpaired, mild cognitive impairment (MCI)). 7 19 of 21 with CDR-SOB (functional) > 0 had abnormal thickness; thus, estimations are inflated and imprecise (odds ratio (OR)=23.69, 95% confidence interval (CI)=2.95-190.06 for CDR-SOB (functional) as continuous measure; OR=11.39, 95% CI=2.41-53.80 for CDR-SOB (functional) > 0 vs 0. 8 Adjusted for age, sex, education, and APOE ε4 allele status. 9 For cognitively unimpaired: global cognitive z-score=1.08 ± 0.88, N=1,514; Short Test of Mental Status score=35.5 ± 2.1, 12 missing. 10 For MCI: global cognitive z-score=-0.70 ± 0.81, N=181; Short Test of Mental Status score=30.5 ± 3.1, 4 missing. whether and in what form it could be part of a battery of tests to predict disease progression or useful for participant selection for AD prevention trials.
